Suppr超能文献

用酶诱导剂治疗酒精性肝硬化。

Treatment of alcoholic cirrhosis with enzyme inducers.

作者信息

Rautio A, Sotaniemi E A, Pelkonen R O, Luoma P V

出版信息

Clin Pharmacol Ther. 1980 Nov;28(5):629-37. doi: 10.1038/clpt.1980.214.

Abstract

The efficacy of hepatic enzyme-inducing drugs in improving liver function and drug metabolism was investigated in 18 chronic alcoholics with cirrhosis. Five subjects treated continuously with the inducing drugs, phenytoin or prednisolone, for concomitant diseases showed more rapid metabolism than the other patients. Phenobarbital (PB) and medroxyprogesterone acetate (MPA), both known inducers, improved drug metabolism in patients with normal or decreased serum albumin. Serum albumin levels rose in alcoholics with low pretherapy levels, whereas serum albumin in subjects with normal pretherapy levels did not change. Serum thrombotest levels rose in six of seven subjects with low pretreatment values. There was a trend toward normal conventional liver tests during the experiment. There was a relationship between in vivo and in vitro drug metabolism in the alcoholics with cirrhosis. Our results demonstrate that by activating liver function, enzyme-inducing drugs may be of therapeutic value in alcoholics with liver cirrhosis and hepatic failure.

摘要

在18名患有肝硬化的慢性酗酒者中,研究了肝酶诱导药物在改善肝功能和药物代谢方面的疗效。5名因伴发疾病而持续接受诱导药物苯妥英或泼尼松龙治疗的受试者,其代谢速度比其他患者更快。苯巴比妥(PB)和醋酸甲羟孕酮(MPA)这两种已知的诱导剂,改善了血清白蛋白正常或降低患者的药物代谢。治疗前血清白蛋白水平较低的酗酒者血清白蛋白水平升高,而治疗前血清白蛋白水平正常的受试者血清白蛋白水平未发生变化。7名治疗前值较低的受试者中有6名血清凝血酶检测水平升高。实验期间常规肝功能检查有趋于正常的趋势。肝硬化酗酒者体内和体外药物代谢之间存在关联。我们的结果表明,通过激活肝功能,酶诱导药物可能对患有肝硬化和肝衰竭的酗酒者具有治疗价值。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验